141 related articles for article (PubMed ID: 31876116)
41. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR
Leukemia; 2011 Apr; 25(4):599-605. PubMed ID: 21252987
[TBL] [Abstract][Full Text] [Related]
42. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia.
Zhang B; Bolognia J; Marks P; Podoltsev N
Cancer Chemother Pharmacol; 2014 Aug; 74(2):303-7. PubMed ID: 24908437
[TBL] [Abstract][Full Text] [Related]
43. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
[TBL] [Abstract][Full Text] [Related]
44. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
[TBL] [Abstract][Full Text] [Related]
45. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
46. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Goto S; Goto H; Yokosuka T
Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
[TBL] [Abstract][Full Text] [Related]
47. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.
Hochberg J; Zahler S; Geyer MB; Chen N; Krajewski J; Harrison L; Militano O; Ozkaynak MF; Cheerva AC; Talano J; Moore TB; Gillio AP; Walters MC; Baxter-Lowe LA; Hamby C; Cairo MS
Bone Marrow Transplant; 2019 Feb; 54(2):226-235. PubMed ID: 29899571
[TBL] [Abstract][Full Text] [Related]
48. Clofarabine/cyclophosphamide for debulking before stem cell transplantation.
Rabitsch W; Böhm A; Bojic M; Schellongowski P; Wöhrer S; Sliwa T; Keil F; Worel N; Greinix H; Hauswirth A; Kalhs P; Jaeger U; Valent P; Sperr WR
Eur J Clin Invest; 2014 Aug; 44(8):775-83. PubMed ID: 24942362
[TBL] [Abstract][Full Text] [Related]
49. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
50. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
[TBL] [Abstract][Full Text] [Related]
51. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
[TBL] [Abstract][Full Text] [Related]
52. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
[TBL] [Abstract][Full Text] [Related]
54. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Cooper T; Kantarjian H; Plunkett W; Gandhi V
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1417-23. PubMed ID: 15571270
[TBL] [Abstract][Full Text] [Related]
55. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
Baytan B; Ozdemir O; Gunes AM; Dönmez O
J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324
[TBL] [Abstract][Full Text] [Related]
56. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
[TBL] [Abstract][Full Text] [Related]
57. Clofarabine: in pediatric patients with acute lymphoblastic leukemia.
Curran MP; Perry CM
Paediatr Drugs; 2005; 7(4):259-64; discussion 265-6. PubMed ID: 16117562
[TBL] [Abstract][Full Text] [Related]
58. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
[TBL] [Abstract][Full Text] [Related]
59. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
60. PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways.
Uzozie AC; Ergin EK; Rolf N; Tsui J; Lorentzian A; Weng SSH; Nierves L; Smith TG; Lim CJ; Maxwell CA; Reid GSD; Lange PF
J Exp Clin Cancer Res; 2021 Mar; 40(1):96. PubMed ID: 33722259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
